Aditya Verma, None;
Muneeswar Gupta Nittala, None;
Swetha Bindu Velaga, None;
Zhihong Hu, None;
Brenda Zhou, None;
Shaun Lampen, None;
Michael Ip, Allergan (C), Astellas Institute for Regenerative Medicine (C), Boehringer Ingelheim (C), Genentech (C), Omeros (C), Quark (C), Thrombogenics (C);
Charles Wykoff, Adverum Biotechnologies, Inc (F), Aerpio Therapeutics (F), Alcon Laboratories (F), Alcon Laboratories, Inc (C), Alimera Sciences, Inc (C), Allergan, Inc (C), Allergan, Inc (F), Apellis Pharmaceutical (C), Apellis Pharmaceutical (F), Bayer AG (C), Clearside Biomedical, Inc (C), Clearside Biomedical, Inc (F), D.O.R.C. International (C), Genentech, Inc (C), Genentech, Inc (F), Novartis International AG (C), Novartis International AG (F), ONL Therapeutics, Inc (C), Ophthotech Corporation (F), Regeneron Pharmaceuticals, Inc (C), Regeneron Pharmaceuticals, Inc (F), Regenxbio Inc (C), Regenxbio Inc (F), Roche (C), Santen Inc (C);
Srinivas Sadda, Allergan (C), Amgen (C), Carl Zeiss Meditec (F), Centervue (C), Centervue (F), Genentech/Roche (C), Heidelberg (C), Nidek (F), Novartis (C), Optos (C), Optos (F), Oxurion (C), Topcon (F)